References
Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, et al.(2003). Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 12: 1551-1564.
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, et al. (2004). The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A 101:14198-14203.
Basso K, & Dalla-Favera R (2015). Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15: 172-184.
Beguelin W, Teater M, Gearhart MD, Calvo Fernandez MT, Goldstein RL, Cardenas MG, et al. (2016). EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell 30: 197-213.
Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD, Jr., & Melnick AM (2017). The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clin Cancer Res 23: 885-893.
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, et al. (2016). Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest 126: 3351-3362.
Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q, et al. (2005). Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7: 445-455.
Cerchietti L, & Melnick A (2013). Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol 6: 343-345.
Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. (2010). A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17: 400-411.
Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, et al. (2009). A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113:3397-3405.
Cheng H, Linhares BM, Yu W, Cardenas MG, Ai Y, Jiang W, et al.(2018). Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. J Med Chem 61: 7573-7588.
Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, et al. (2009). The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 113: 5536-5548.
Coiffier B, & Sarkozy C (2016). Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program 2016: 366-378.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. (2017). Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130: 1800-1808.
Deb D, Rajaram S, Larsen JE, Dospoy PD, Marullo R, Li LS, et al.(2017). Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. Cancer Res 77: 3070-3081.
Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et al. (1997). Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 94:10762-10767.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. (2011). BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473: 384-388.
Fernando TM, Marullo R, Pera Gresely B, Phillip JM, Yang SN, Lundell-Smith G, et al. (2019). BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. Cancer Discov 9: 662-679.
Homola J (2003). Present and future of surface plasmon resonance biosensors. Anal Bioanal Chem 377: 528-539.
Huang C, Hatzi K, & Melnick A (2013). Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol 14: 380-388.
Huang C, & Melnick A (2015). Mechanisms of action of BCL6 during germinal center B cell development. Sci China Life Sci 58:1226-1232.
Huynh KD, Fischle W, Verdin E, & Bardwell VJ (2000). BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 14:1810-1823.
Kamada Y, Sakai N, Sogabe S, Ida K, Oki H, Sakamoto K, et al.(2017). Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach. J Med Chem 60: 4358-4368.
Kerres N, Steurer S, Schlager S, Bader G, Berger H, Caligiuri M, et al. (2017). Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6. Cell Rep 20: 2860-2875.
Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, et al. (2011). Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity 34: 961-972.
Leeman-Neill RJ, & Bhagat G (2018). BCL6 as a therapeutic target for lymphoma. Expert Opin Ther Targets 22: 143-152.
Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontan L, et al.(2018). PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood 132: 2026-2039.
Madapura HS, Nagy N, Ujvari D, Kallas T, Krohnke MCL, Amu S, et al. (2017). Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene 36: 4619-4628.
McCoull W, Abrams RD, Anderson E, Blades K, Barton P, Box M, et al. (2017). Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. J Med Chem 60: 4386-4402.
Mendgen T, Steuer C, & Klein CD (2012). Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 55: 743-753.
Mlynarczyk C, Fontan L, & Melnick A (2019). Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunol Rev 288: 214-239.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377: 2531-2544.
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, & Dalla-Favera R (2003). Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101: 2914-2923.
Phan RT, & Dalla-Favera R (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432: 635-639.
Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, et al. (2004). Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10: 1329-1335.
Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, et al. (2007). Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A 104: 3207-3212.
Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, et al. (2007). Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 8: 705-714.
Ranuncolo SM, Polo JM, & Melnick A (2008). BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis 41: 95-99.
Song W, Wang Z, Kan P, Ma Z, Wang Y, Wu Q, et al. (2018). Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway. Biomed Res Int 2018: 6953506.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, & Flowers CR (2016). 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66: 443-459.
Tomasic T, & Peterlin Masic L (2012). Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opin Drug Discov 7: 549-560.
Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, & Calame KL (2004). Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 173: 1158-1165.
Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, et al.(2017). BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discov 7: 506-521.
Wagner SD, Ahearne M, & Ko Ferrigno P (2011). The role of BCL6 in lymphomas and routes to therapy. Br J Haematol 152: 3-12.
Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, et al. (2015). The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene 34: 1073-1082.
Wang YQ, Xu MD, Weng WW, Wei P, Yang YS, & Du X (2015). BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. Am J Cancer Res 5: 255-266.
Wu HB, Lv WF, Wang YX, Li YY, & Guo W (2018). BCL6 promotes the methotrexate-resistance by upregulating ZEB1 expression in children with acute B lymphocytic leukemia. Eur Rev Med Pharmacol Sci 22:5240-5247.
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, et al. (2017). BCL6 promotes glioma and serves as a therapeutic target. Proc Natl Acad Sci U S A 114: 3981-3986.
Yasui T, Yamamoto T, Sakai N, Asano K, Takai T, Yoshitomi Y, et al. (2017). Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design. Bioorg Med Chem 25: 4876-4886.
Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, et al. (1993). Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262: 747-750.